Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives
Glucagon-like peptide-1
0301 basic medicine
0303 health sciences
Biodistribution
Diabetes
Insulin
Therapeutics. Pharmacology
RM1-950
Review
Delivery platforms
Oral peptides
DOI:
10.1016/j.apsb.2024.02.019
Publication Date:
2024-02-28T02:13:07Z
AUTHORS (6)
ABSTRACT
Diabetes, characterized by hyperglycemia, is a major cause of death and disability worldwide. Peptides, such as insulin and glucagon-like peptide-1 (GLP-1) analogs, have shown promise as treatments for diabetes due to their ability to mimic or enhance insulin's actions in the body. Compared to subcutaneous injection, oral administration of anti-diabetic peptides is a preferred approach. However, biological barriers significantly reduce the efficacy of oral peptide therapeutics. Recent advancements in drug delivery systems and formulation techniques have greatly improved the oral delivery of peptide therapeutics and their efficacy in treating diabetes. This review will highlight (1) the benefits of oral anti-diabetic peptide therapeutics; (2) the biological barriers for oral peptide delivery, including pH and enzyme degradation, intestinal mucosa barrier, and biodistribution barrier; (3) the delivery platforms to overcome these biological barriers. Additionally, the review will discuss the prospects in this field. The information provided in this review will serve as a valuable guide for future developments in oral anti-diabetic peptide therapeutics.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (193)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....